Introduction
============

Prostate cancer (PCa) is the most prevalent malignancy in the male population, with 164,690 newly estimated cases and 29,430 newly estimated deaths in the United States, 2018 [@B1]. PCa mainly occurs in elderly men, and nearly two thirds of cases are diagnosed at the age of 65 or over [@B2]. Up to now, several factors have been verified associated with the carcinogenesis of PCa, including aging, family history and race [@B3]-[@B5]. Furthermore, the altered androgen metabolism also plays a pivotal role [@B6]. However, the definite etiological mechanism remains unclear. With the assistance of epidemiological studies, a large number of potential risk factors for PCa, such as work environment, obesity, smoking, alcohol consumption and sexual activity, have been identified in the past decades [@B7]-[@B11]. Unexpectedly, prostatitis and benign prostatic hyperplasia (BPH) were listed among these risk factors, though controversies existed [@B12], [@B13].

Prostatitis and BPH are two common benign diseases of the prostate gland. Prostatitis affects men of all ages, especially the middle age group. Both of them have high incidence ranging from 3 to 16% in Europe, North America and Asia [@B14]-[@B16]. Moreover, more than 50% of the surgical prostate specimens were found to be associated with histological inflammation [@B17]. Pathogenesis of prostatitis includes pathogens infection like bacteria and mycoplasma, urine reflux, autoimmunity, neuro muscular mechanisms and so on [@B18]-[@B20]. However, BPH predominantly occurs in elderly men, and 70% of the patients are 70 years old or over [@B21]. Aging and androgen are established factors leading to the occurrence of BPH [@B22]. Furthermore, metabolic syndrome, genetics and lifestyle may also have something to do with BPH [@B23], [@B24]. As for the correlation between prostatitis and BPH, Adorini et al. suggested a significant role of inflammation in the occurrence and progression in BPH [@B25]. What\'s more, Jennifer et al. found an increased risk of BPH in those men with a history of prostatitis [@B26]. However, it has yet to be further determined.

As a clinician, we are often enquired of by the anxious patients with prostatitis or BPH, \'Whether or not our disease would develop into PCa?\'. Facing these questions, we often told them that prostatitis, BPH and PCa had nothing to do with each other, due to the absence of definite evidence. However, accumulating epidemiological studies have revealed the significant associations among prostatitis, BPH and PCa risk. Nevertheless, controversies still exist, and no consensus has been achieved on this topic till now. Hence, we comprehensively searched online databases and conducted this meta-analysis to clarify their correlations.

Materials and methods
=====================

Literature search strategy
--------------------------

We comprehensively retrieved relevant studies about the relations among prostatitis, BPH and PCa from online databases PubMed, PMC, EMBASE and Web of Science, published before April 1st, 2019, 2018. Following keywords combined with the Medical Subject Headings (MeSH) items were utilized: "Prostatitis" or "Prostatitides" or "Chronic Pelvic Pain Syndrome" or "Chronic Bacterial Prostatitis" or "Acute Bacterial Prostatitis" or "Asymptomatic Inflammatory Prostatitis", "Benign Prostatic Hyperplasia" or "BPH" or "Prostatic Hyperplasia" or "Prostatic Hypertrophy", "Prostate Cancer" or "Prostate Neoplasm" or "prostate tumor" or "PCa". Furthermore, potentially eligible studies were meticulously identified by checking the reference lists from relevant review studies.

Inclusion and exclusion criteria
--------------------------------

Included studies must meet the following criteria: (1) Used a case-control or cohort study design; (2) Evaluated the epidemiological association among prostatitis, BPH and PCa. (3) Presented concrete numbers of exposures and non-exposures in both case and control groups to calculate the pooled odds ratios (ORs) and 95% confidence intervals (CIs); (4) Enrolled patients with PCa were confirmed by histopathological examination. In addition, exclusive criteria were as follows: (1) Not case-control or cohort studies; (2): Cross-sectional studies; (3) Duplicated studies or invalid data; (4) Studies not related to prostatitis, BPH and PCa.

Data Extraction and Quality Assessment
--------------------------------------

All available data from the included studies were extracted independently by two reviewers (L.Z and Y.W) and summarized together. A third reviewer (ZQ.Q) would join in the discussion if any divergence arose and then reached a consensus. Finally, the extracted data were recorded in a standardized format including following items: first author\'s name, publication year, age of subjects, country, ethnicity, source of controls, study design, data source, the number of cases and controls, and the number of exposures. In addition, the quality of included studies was assessed with the Newcastle-Ottawa Scale (NOS). If the final score \> 6, it was regarded as high-quality and then included in the subsequent meta-analyses.

Statistical Analysis
--------------------

Pooled ORs with 95% CIs were respectively calculated to evaluate the associations between prostatitis and PCa, BPH and PCa, prostatitis and BPH. Heterogeneity was tested by Cochrane Q test and Higgins *I^2^* statistic. If the heterogeneity was acceptable (*I^2^*\<50% or P\>0.10), the fixed effect model (a Mantel-Haenszel method) was adopted. Contrarily, the random effect model (a DerSimonian-Laird method) would be applied if heterogeneity was significant (*I^2^*\>50% or*P*\<0.10). Subgroup analyses were performed by ethnicity, study design, source of control (SOC), and sample size. Furthermore, the stability and reliability of the results was examined by sensitive analyses. The publication bias was assessed by Begg\'s funnel plots and Egger\'s linear regression test. A significant bias would be considered if the *P*\<0.05. All data were processed by Stata software 12.0 (StataCorp LP, College Station, TX).

Results
=======

Studies characteristics
-----------------------

Based on the above-mentioned inclusion and exclusion criteria, a total of 42 studies (S1-S42, **[Table S1](#SM0){ref-type="supplementary-material"}**) were included in the quality assessment. Results of the quality assessment were shown in **[Table S2](#SM0){ref-type="supplementary-material"}**. Ultimately, 35 high-quality studies with NOS scores \> 6 were selected for further meta-analyses, while 7 studies (S36-S42) were eliminated. Among them, 27 studies described the relation between prostatitis and PCa, 21 eligible studies focused on the association between BPH and PCa, and 2 studies depicted the relation of prostatitis and BPH. **Figure [1](#F1){ref-type="fig"}** presented the specific details of searching literature and screening steps. The main characteristics of all included studies were separately listed in **Table [1](#T1){ref-type="table"}**, **2** and**3**.

Association between prostatitis and PCa
---------------------------------------

Pooled ORs and 95% CIs were calculated to assess the association between prostatitis and PCa. As shown in **Figure [2](#F2){ref-type="fig"}**, the overall analysis revealed a significant association between prostatitis and PCa (OR=1.72, 95% CI=1.44-2.06). However, a huge heterogeneity was detected in the results (*I²*=90.1%, *P*\<0.001). Subsequent subgroup analyses failed to decrease the heterogeneity. Moreover, meta-regression analysis revealed the country and ethnicity might explain a certain proportion of the heterogeneity ([Table S3](#SM0){ref-type="supplementary-material"}). However, the heterogeneity remained remarkable when stratified by ethnicity.

Given these, we performed Galbraith radial plot to spot the outliers as the potential sources of heterogeneity (**Figure [3](#F3){ref-type="fig"}**). After eliminating partly of the studies according to the Galbraith plot, 17 residual studies were re-analyzed. New results remained significant (OR=1.59, 95% CI=1.48-1.70), and the overall heterogeneity was successfully decreased (*I²*=29.4%, *P*=0.123). What\'s more, subgroup analyses including ethnicity, study design and sample size showed significant results, which further validated this association (**Figure [4](#F4){ref-type="fig"}**).

Association between BPH and PCa
-------------------------------

The overall analysis revealed a conspicuous association between BPH and PCa (OR=2.16, 95% CI=1.75-2.68). However, the great heterogeneity (*I²*=97.1%, *P*\<0.001) also appeared and could not be reduced by subgroup analyses (**Figure [5](#F5){ref-type="fig"}**). What\'s more, meta-regression analyses suggested that no relevant covariates which could be summarized based on the between-study generality and individuality, could explain even part of the heterogeneity (**[Table S3](#SM0){ref-type="supplementary-material"}**).

Likewise, we excluded studies with distinct heterogeneity based on Galbraith plot in combination with results of Begg\'s funnel plot and sensitive analysis (**Figure [6](#F6){ref-type="fig"}**). Ultimately, post-elimination results of overall analysis (OR=3.10, 95% CI=2.87-3.35, *I²*=8.4%, *P*=0.365) and subgroup analyses maintained positive, which illustrated the significant association between BPH and PCa (**Figure [7](#F7){ref-type="fig"}**).

Association between prostatitis and BPH
---------------------------------------

Case-control studies and a cohort studies described the epidemiological relation of prostatitis with BPH. Significant results were obtained in the overall analysis (OR=2.95, 95% CI=1.94-4.47, *I²*=44.1%, *P*=0.181) (**Figure [8](#F8){ref-type="fig"}**). In addition, both the case-control study (OR=4.93, 95% CI=2.13-11.41) and the cohort study (OR=2.56, 95% CI=1.59-4.10) supported that prostatitis could enhance the risk of BPH.

Sensitivity analysis
--------------------

Sensitivity analyses were performed to evaluate the stability of results and reflect the impact of the individual study to overall results by deleting each study once a time. Our results indicated that no single study significantly influenced the pooled ORs and 95% CIs. Sensitivity analyses of the relation between prostatitis or BPH and PCa were respectively presented in**Figure [3](#F3){ref-type="fig"}A, 3B, 6A, 6B.**

Publication bias
----------------

The Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias. In the pooled analysis of prostatitis and PCa, Egger\'s *P* value was 0.17 and Begg\'s *P* value was 0.09 after dealing with the heterogeneity (**Figure [3](#F3){ref-type="fig"}E**). In the pooled analysis of BPH and PCa, Egger\'s *P* value was 0.763 and Begg\'s *P* value was 0.902 after elimination. (**Figure [6](#F6){ref-type="fig"}E**). Therefore, the original studies included in the present meta-analysis have no obvious publication bias.

Discussion
==========

Clinically, urologic physicians always asked by some anxious patients whether prostatitis or BPH will develop into PCa or increase the risk of PCa. However, there are no explicit answers on these questions to date. Herein, we carefully searched available literature to seek for explanations. Although no convincingly pathological evidence, a large number of epidemiological studies have revealed the close associations between prostatitis, BPH and PCa [@B27]-[@B29]. However, no consensus has been reached. Hence, this meta-analysis was conducted to further clarify their triadic relationships by comprehensively summarizing the epidemiological studies.

As indicated in the results, prostatitis and BPH were both associated with escalating risks of PCa. Moreover, people with a history of prostatitis might be more vulnerable to BPH. All the results of subgroup analyses were positive. However, huge heterogeneity was existed among enrolled studies. Meta-regression results suggested only the country and ethnicity could o explain small parts of the heterogeneity. After careful analysis of all available data, the potential sources of the heterogeneity were displayed below. First, due to the extreme correlations of these three diseases with age, the different distribution of participants\' age was regarded as a vital source of the heterogeneity. On the other hand, prostatitis could be divided into four categories: acute bacterial prostatitis, chronic bacterial prostatitis, Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) and asymptomatic inflammatory prostatitis, according to the National Institutes of Health (NIH) [@B30]. Among included studies, no specific classification of prostatitis was identified, which might lead to inhomogeneity. On the other hand, the years of prostatitis or BPH history before getting PCa also affect the results to a great extent, while a good deal of studies had not paid attention to it. Rothman et al. found a highest relative risk for prostate cancer in men who had prostatitis diagnosed within 12 months of their prostate cancer reference data [@B31]. Moreover, pathological types of PCa were also rarely mention in these studies. Furthermore, methodological heterogeneity and other various factors such as ways of getting data from participants, bias of participants\' memories of medical history and differences of interviewers\' emphasis all inevitably contributed to the source of the heterogeneity.

Galbraith plot as one way of displaying several estimates of the same quantity having different standard errors, was also used to spot the outlier as the possibly major source of between-study heterogeneity [@B32], [@B33]. Thus, Galbraith plot associated with funnel plot and sensitive analysis was applied to filter those papers with higher heterogeneity and tried to pool analysis with those of approximately homogeneous papers. After carefully screening by the Galbraith plot and considering results from sensitive analyses as well as Begg\'s funnel plots together, 17 studies (*I^2^*=29.4%, *P*=0.123) with low heterogeneity were ultimately re-analyzed to display the relationship of prostatitis and PCa, and 8 studies were to re-analyzed the association between BPH and PCa (*I^2^*=8.4%, *P*=0.365). Finally, the results of overall and subgroup analyses remained significant. As for studies about prostatitis and BPH, although large heterogeneity existed as well, pooled OR with 95% CI of each independent study was all above 1, indicating that prostatitis could enhance the risk of BPH anyway.

Notably, the outcomes of us remained consistent before and after adjustment for heterogeneity and meanwhile positive results were obtained in both the overall and subgroup analyses, indicating the stability and reliability of our results. With the increasing recognition of the early-diagnosis and early-treatment of PCa, it had caught more and more attention in the recent years [@B34]. Although several factors had been verified associated with the carcinogenesis of PCa involving aging, family history, race and altered androgen metabolism, its definite pathogenesis remained unclear [@B3]-[@B5]. While the views "prostatitis could lead to higher PCa risk" or "BPH could increase the PCa susceptibility" had not been acknowledged, a massive number of epidemiological studies had been carried to explore whether prostatitis and BPH were risk factors of PCa. The latest cohort study with 2500 participants suggested that higher proportion in men with prostatitis were diagnosed with PCa after 15 years later [@B35]. Besides, a cohort study conducted in Denmark with more than a hundred thousand participants from 1980 through 2006 also demonstrated that the incidence rate was higher in the BPH cohort [@B28]. According to above results, the associations between prostatitis or BPH and PCa were almost conclusive.

Some potential hypotheses had been put forward in the decades, regarding the correlations between prostatitis, BPH and PCa. Inflammation was seen as highly correlated with several types of cancers including colon, stomach, liver and bladder [@B36]-[@B39]. Chronic Inflammatory stimulating could induce various chemokines and cytokines generation that provided a favorable microenvironment for tumor growth and tumor progression by facilitating angiogenesis and increasing the production of reactive oxygen species (ROS), which can lead to oxidative DNA damage and reduced DNA repair [@B40]. Chronic inflammatory lesions could be commonly detected in PCa patients when carrying out prostate biopsy [@B41]. Jiang et al. conducted a meta-analysis of 20 case-control studies and found a significant positive relationship between prostatitis and PCa [@B12]. Herein, we included larger numbers of studies and demonstrated a likewise significant relationship of prostatitis with PCa. However, which type of prostatitis was more inclined to associate with a higher risk of PCa remained to be determined.

As for BPH and PCa, strong arguments that BPH and PCa were unrelated, have been insisted in most urological surgeons on account of differences in the histologic and anatomic location of these 2 conditions that BPH mostly occurs in transitional zone of prostate while PCa often happen in peripheral zone [@B42]. Besides, BPH was primarily characterized by hyperplasia of stromal, whereas PCa predominantly involves in the epithelium [@B42]. Nonetheless, parallel features existed in the two diseases like hormone-dependent growth, response to androgen-deprivation treatments and relation with old age [@B43]. Whether or not BPH could affect tumorigenesis via reacting to epithelium-stromal, it remained undetermined [@B44]. On the other hand, plenty of studies investigated the epidemiological relationship between BPH and PCa, and found a positive effect of BPH on PCa risk [@B28], [@B45]. Accordingly, we pooled all the results of available case-control or cohort studies to further shed light on their relationship and the results showed significant relation. However, those patients with a history of BPH were more likely to consult urologic physicians and perform a regular examination. As a result, increased the detection rate of PCa was found and this might lead to detection bias compared with healthy controls.

Our results suggested that prostatitis and BPH could increase the risk of PCa. Then, what\'s the connection between prostatitis and BPH? Nunzio et al. found common inflammatory infiltrates in BPH lesions and those cytokines and growth factors released by inflammatory cells could stimulate the stroma and epithelial cells to hyperproliferation [@B46]. Taoka et al. reported that asymptomatic histological inflammation could induce repeated damage, repair, and regeneration of the prostate tissue, causing prostatic hyperplasia and leading to morphological changes of stromal tissue, which could increase urination resistance and result in symptomatic BPH [@B47]. Nevertheless, whether prostatitis could lead to BPH has not been widely approved by urological specialists. Hence, we searched for eligible epidemiological studies to illuminate the potential relationship. A large number of cross-sectional studies have suggested that prostatitis and BPH are closely related with each other [@B48]-[@B50]. A total of 1 case-control study and 1 cohort study were included in meta-analysis meeting the inclusion criteria. It was found that the BPH cases were more likely exposed to a prostatitis history than non-BPH controls [@B51]. Furthermore, Sauver and his colleague conducted a 14-years follow-up cohort study and demonstrated the longitudinal association between prostatitis and development of BPH [@B26].

There were mainly four advantages in this article. On the one hand, this study was the first time to explore the associations between prostatitis, BPH and PCa at the same time from an epidemiological perspective and significant results were acquired. On the other hand, our study was performed with the extremely strict inclusion criteria which eliminating the cross-section studies in some surveys. Moreover, we performed strict quality evaluation by excluding low-quality studies (NOS\<7) while the previous reviews did not focus on the quality evaluation. What\'s more, we preformed in-depth statistical analysis and careful comparison of multiple heterogeneous studies and tried our best to discussed the source of heterogeneity. However, the previous studies of meta-analysis describing similar topic did not detailly explain the source of the heterogeneity and deal with it. Herein, we firstly applied the approach of Galbraith plot to exclude the outlier-studies and compared the results pre and post-elimination. Thus, the integrated results are bound to elevated the reliability of our conclusions.

To a certain degree, several limitations of this paper should be considered: Firstly, the results were based on unadjusted estimates without modifying the influences of some other covariates like age and race; Secondly, the heterogeneity among enrolled studies was so huge that we have to eliminate some studies with higher heterogeneity and we could not present more detailed subgroup after analyzing the possible source of heterogeneity; Thirdly, prostatitis, BPH and PCa were all multifactorial diseases that other factors like age, environment, lifestyle and inheritance should also be taken into account as a whole. Fourthly, most included studies were case-control study which were less reliable than cohort studies. Thus, more high-quality cohort studies were required to shed light on the association between prostatitis, BPH and PCa. Last but not least, this paper illustrated their triadic relationships only from the epidemiological perspective and could not clarify whether or not progressive associations existed among prostatitis, BPH and PCa, as hepatitis, liver cirrhosis and hepatocellular carcinoma did.
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###### 

Main characteristics of eligible studies explore the association between prostatitis and prostate cancer.

  Author               Year   Age     Country     Ethnicity   SOC   Design         Data source      No. cancer cases   No. controls   No. prostatitis in cases   No. prostatitis in controls
  -------------------- ------ ------- ----------- ----------- ----- -------------- ---------------- ------------------ -------------- -------------------------- -----------------------------
  \*Doat^S1^           2017   40-75   France      Caucasian   PB    case-control   interview        819                879            84                         63
  Nair-Shalliker^S2^   2017   19-94   Australia   Caucasian   PB    case-control   interview        1181               875            97                         25
  Rybicki^S3^          2016   NA      US          Mixed       PB    case-control   Medical record   574                574            102                        105
  \*Boehm^S4^          2016   \<76    Canada      Caucasian   PB    case-control   interview        1884               1965           223                        134
  \*Spence^S5^         2014   40-79   Canada      Caucasian   PB    case-control   interview        1555               1586           195                        115
  Hung^S6^             2013   \>50    China       Asian       PB    case-control   Medical record   1184               4376           137                        99
  Hennis^S7^           2013   NA      Barbadian   African     PB    case-control   interview        963                941            75                         23
  \*Wright^S8^         2012   34-74   US          Caucasian   PB    case-control   interview        1754               1645           217                        132
  \*Chao^S9^           2010   45-69   US          Mixed       PB    case-control   interview        1559               75384          139                        4788
  Weinmann^S10^        2010   45-84   US          Mixed       PB    case-control   Medical record   768                929            119                        145
  \*Huang^S11^         2008   61-69   US          Caucasian   PB    case-control   interview        868                1283           78                         89
  \*Sutcliffe^S12^     2007   40-75   US          Caucasian   PB    case-control   interview        691                691            152                        124
  Sarma^S13^           2006   40-79   US          African     PB    case-control   interview        129                706            34                         47
  \*Patel^S14^         2005   50-74   US          Mixed       PB    case-control   interview        700                604            86                         38
  Rothman^S15^         2004   40-64   US          Caucasian   PB    case-control   interview        750                702            660                        644
  \*Roberts^S16^       2004   63-77   US          Caucasian   PB    case-control   Medical record   409                803            41                         50
  Lightfoot^S17^       2004   45-84   Canada      Caucasian   PB    case-control   interview        760                1632           30                         88
  \*Rosenblatt^S18^    2001   40-64   US          Caucasian   PB    case-control   interview        753                703            87                         57
  \*Zhu^S19^           1999   40-69   US          Caucasian   PB    case-control   interview        159                277            37                         41
  \*Lee^S20^           1998   45-89   China       Asian       PB    case-control   interview        133                265            32                         16
  \*Zhu^S21^           1996   40-69   US          Caucasian   PB    case-control   interview        175                258            15                         22
  John^S22^            1995   \<85    US          Mixed       PB    case-control   interview        1642               1636           418                        177
  \*Hiatt^S23^         1994   NA      US          Mixed       PB    case-control   interview        177                177            14                         13
  \*Honda^S24^         1988   \<60    US          Caucasian   PB    case-control   interview        211                211            39                         18
  \*Vaarala^S25^       2016   20-80   Finland     Caucasian   PB    cohort         interview        40                 1732           13                         238
  \*Cheng^S26^         2010   45-69   US          Mixed       PB    cohort         interview        1631               63613          147                        4081
  Sutcliffe^S27^       2006   40-75   US          Caucasian   PB    cohort         interview        2230               33356          421                        5311

NA: Not available; SOC: Source of controls; PB: Population-based; HB: Hospital-based;^S\#^: Reference.

\*Adjustment for heterogeneity performed by excluding relevant studies as the outliers spotted by Galbraith plot and the possible major source of heterogeneity.

###### 

Main characteristics of eligible studies explore the association between BPH and prostate cancer;

  Author                 Year   Age      Country     Ethnicity   SOC   Design         Data source      No. cancer cases   No. controls   No. BPH in cases   No. BPH in controls
  ---------------------- ------ -------- ----------- ----------- ----- -------------- ---------------- ------------------ -------------- ------------------ ---------------------
  \*Nair-Shalliker^S2^   2017   19-94    Australia   Caucasian   PB    case-control   interview        1181               875            436                124
  \*Hung^S6^             2013   \>50     China       Asian       PB    case-control   Medical record   1184               4763           1084               1071
  \*Hennis^S7^           2013   NA       Barbadian   African     PB    case-control   interview        963                941            428                186
  Chao^S9^               2010   45-69    US          Mixed       PB    case-control   interview        1559               75384          514                14728
  Weinmann^S10^          2010   45-84    US          Mixed       PB    case-control   Medical record   768                929            284                282
  Huang^S11^             2008   61-69    US          Caucasian   PB    case-control   interview        868                1283           258                306
  \*Patel^S14^           2005   50-74    US          Mixed       PB    case-control   interview        700                604            246                101
  Coker^S28^             2004   65-79    US          Mixed       PB    case-control   interview        407                393            159                102
  Lightfoot^S17^         2004   45-84    Canada      Caucasian   PB    case-control   interview        710                1543           103                315
  \*Rosenblatt^S18^      2001   40-64    US          Caucasian   PB    case-control   interview        753                703            253                122
  \*Zhu^S19^             1999   40-69    US          Caucasian   PB    case-control   interview        156                281            77                 75
  Lee^S20^               1998   45-89    China       Asian       HB    case-control   interview        133                265            64                 36
  Zhu^S21^               1996   40-69    US          Caucasian   PB    case-control   interview        175                258            30                 35
  John^S22^              1995   \<85     US          Mixed       PB    case-control   interview        1642               1636           539                309
  Hiatt^S23^             1994   NA       US          Mixed       PB    case-control   interview        177                177            68                 61
  \*Honda^S24^           1988   \<60     US          Caucasian   PB    case-control   interview        211                211            56                 19
  Mishina^S29^           1985   45-89    Janpan      Asian       PB    case-control   interview        100                100            28                 3
  Schenk^S30^            2011   ≥55      US          Caucasian   PB    cohort         interview        1225               2618           394                761
  Ørsted^S31^            2011   20-100   Denmark     Caucasian   PB    cohort         interview        53171              794616         24486              161489
  Greenwald^S32^         1974   \<80     US          Caucasian   HB    cohort         Medical record   50                 1590           24                 814
  \*Armenien^S33^        1974   NA       US          Caucasian   HB    cohort         Medical record   45                 566            35                 271

NA: Not available; SOC: Source of controls; PB: Population-based; HB: Hospital-based; ^S\#^: Reference.

\*Adjustment for heterogeneity performed by excluding relevant studies as the outliers spotted by Galbraith plot and the possible major source of heterogeneity.

###### 

Main characteristics of eligible studies explore the association between prostatitis and BPH;

  Author        Year   Age     Country   Ethnicity   SOC            Design   Data source      No. BPH cases   No. controls   No. prostatitis in cases   No. prostatitis in controls
  ------------- ------ ------- --------- ----------- -------------- -------- ---------------- --------------- -------------- -------------------------- -----------------------------
  Sauver^S34^   2008   40-79   US        Caucasian   cohort         PB       Medical record   1921            527            176                        20
  Ning^S35^     2003   60+     China     Asian       case-control   PB       interview        100             100            30                         8

NA: Not available; SOC: Source of controls; PB: Population-based; HB: Hospital-based; ^S\#^: Reference.

[^1]: \*These authors contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
